Increases in serum neopterin concentrations are a regular finding in patients with ovarian cancer. The strong correlation between neopterin and tumor progression might be explained by a direct influence of the pteridine compound on tumor cell growth. In the present study we investigated whether neopterin affects the production of the angiogenic promotors vascular endothelial growth factor (VEGF) and erythropoietin (EPO) in the human ovarian carcinoma cell line OVCAR-3. VEGF and EPO gene expression were detected via RT-PCR. and a possible involvement of hypoxiainducible factor-1 was assessed by electrophoretic mobility shift assays. Neopterin amplified the hypoxia-induced VEGF and EPO gene expression as well as protein synthesis in a concentration-dependent manner. In addition, generation of both VEGF and EPO could be detected following incubation of cells with neopterin under normoxic conditions, too. Neopterin-induced synthesis of VEGF and EPO was preceeded by a stimulation of hypoxiainducible factor-1 uptake into the nucleus of OVCAR-3 cells. From these data we conclude that neopterin acts as a mediator of angiogenesis. Stimulation of VEGF and EPO generation in ovarian carcinoma cells may promote vascularization of the malignant tissue and thus tumor growth and development.
Introduction
Neopterin is a pyrazino pyrimidine compound biosynthesized and released in large amounts from human monocytes/macrophages following activation with T-lymphocyte-derived interferon-γ. IFN-γ < 1 ). Thus, serum and urinary neopterin levels serve as an indicator in patients with diseases associated with an increased activity of the cellular immune system (2) . In ovarian carcinoma, raised neopterin levels have been reported and a significant correlation between increased neopterin concentrations and progression as well as outcome of the disease were shown (3) (4) (5) . Previous investigations have supported the concept that neopterin itself exhibits distinct biochemical properties, most likely via interactions with the cellular redox state (6) . These direct actions of neopterin may provide an explanation for the observed correlation between high neopterin levels and unfavorable cancer prognosis. Angiogenesis is an essential prerequisite for the delivery of nutrients and oxygen to the developing tumor tissue (7) . Among the growth factors implicated in the onset of angiogenesis in ovarian tumor tissue, vascular endothelial growth factor (VEGF) seems to play the pivotal role. VEGF m RNA is upregulated in ovarian carcinoma (8) , and anti-VEGF antibodies inhibited ascites formation in an animal model of ovarian cancer (9) . Apart from VEGF, the tumor cells secrete other factors that accumulate in the target vascular endothelium thus stimulating endothelial cell growth in a paracrine manner. Among them, the hematopoietic cytokine erythropoietin (EPO) may play an important role. EPO receptor has been detected at the surface of endothelial cells (EC) (10, 11) . Furthermore, EPO was shown to stimulate proliferation and migration of human and bovine EC as well as in vitro angiogenesis of the rat thoracic aorta (12, 13) . Estrogen-dependent production of EPO found in the uterus is presumedly involved in uterine angiogenesis (14) . Hypoxia-inducible factor-1 (HIF-1) is described to be one key regulator for the expression of both VEGF and EPO m RNA (15, 16) . mRNA levels for HIF-la and HIF-1 β are relatively constant and not affected by changes in cellular p0 2 . In contrast to HIFlß protein, which is stable irrespective of oxygen pressure, HIF-1 α is rapidly degraded via a ubiquitin-proteasome pathway under normoxic conditions ( 17) . Under hypoxia. HIF-1 α protein is stabilized, the HIF-1 heterodimer accumulates, is translocated into the nucleus, and activates the expression of HIF-sensitive genes.
In a hepatocellular carcinoma cell line, neopterin was found to suppress hypoxia-induced EPO synthesis ( 18) . Assuming that neopterin is a promoter of tumor cell growth, this sounds paradoxical, since one would expect a benefit from the inhibition of a pro-angiogenic factor. To obtain additional information about the influence of neopterin on the growth of ovarian cancer, the present study investigated the effects of neopterin on HIF-1 activation as well as VEGF and EPO gene expression in a human ovarian carcinoma cell line.
Materials and methods

Cell cultures
The human ovarian carcinoma cell line OVCAR-3 (American Type Culture Collection No. HTB-161) was cultured under standard conditions in RPMI medium with addition of 10% fetal calf serum, 50 pg/rnl streptomycin, and 50 U/ml pcnicillin in a humidified atmosphere at 37°C on either polystyrene culture flasks and wells or petriPERM tissue culture dishes (52 mm, Heraeus, Hanau, Germany). The bottom of the petriPERM culture dish is made of a gas-permeable Teflon membrane (25 μηι thickness) that allows adjustment of the pericellular p0 2 to the p0 2 level within the CO 2 -incubator. Cells grown on petriPERM dishes were placed in a gas-tight acrylic chamber at continuous flow. Normoxic conditions were obtained by incubating the cells in an atmosphere of 5% CO-, in air, while hypoxic incubations were performed with a pre-mixed gas of 2% 0 2 , 5% C0 2 , and 93% N 2 . Cells were treated with neopterin at the following concentrations: 1, 10, and 100 μΜ. None of these concentrations was cytotoxic to ovarian carcinoma cells as assessed by means of a tetrazoline bromide viability assay.
Reverse transcription
and polymerase chain reaction Cells were washed in sterile PBS and lysed with 4 M guanidine isothiocyanate containing 0.1 M 2-mercaptoethanol. Total RNA was extracted and purified by acid phenol-chloroform extraction. One μg total RNA (concentration was determined photometrically at a wavelength of 260 nm) was reverse-transcribed into cDNA using oligo (dT)15 as primer for reverse transcriptase (RT). RT-generated cDNAs encoding fothuman VEGF and EPO were amplified using polymerase chain reaction (PCR) as described recently (19) . The amplified products were resolved by 3% agarose gel electrophoresis and visualized by ethidium bromide (0.5 pg/ml) staining. For quantitation of VEGF and EPO cDNAs, a competetive PCR was performed using a non-homologous DNA fragment derived from the viral oncogene v-Erb Β to which the human VEGF or EPO primer templates have been added (Competetive DNA MIMIC, Clonetech, Heidelberg, Germany). Densitometrie analysis of the scanned photographs was done using the GelDoc 1000 (BioRad, Munich, Germany) system (length of VEGF cDNA is 342 base pairs, length of VEGF competitor fragment is 442 base pairs; length of EPO cDNA is 253 base pairs, length of EPO competitor fragment is 442 base pairs ). Results were calculated by detecting the point of equivalence between competitor and target cDNAs according to their respective band intensities. Data are given as amol cDNA/pg total RNA taking into consideration that I μΙ of the 25 μΙ RT reaction yield was used per quantitative PCR.
Oligonucleotide primers for VEGF and internal VEGF standard were: 5' GAGGAGGGCAGAATCAC 3' (upstream), and 5' AGGCCCACAGGGATTTTCTT-GTC 3' (downstream), oligonucleotide primers for EPO and internal EPO standard were: 5' CTGCTC-CACTCCGAACAATCAC 3 ' (upstream), and 5' CTG-GAGTGTCCATGGGACAG 3' (downstream), and oligonucleotide primers for GAPDH were: 5' GCAGGGGGAGCCAAAAGGG 3' (upstream) and 5' TGCCAGCCCCAGCGTCAAAG 3 (downstream).
Preparation
of nucleic extracts Cells were rinsed with cold PBS and lysed directly on the culture dishes in 1 ml cold lysis buffer (0.6% Nonidet P-40. 150 mM NaCl. 10 mM Tris pH 7.9, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride). Lysed cells were transferred into a 2 tnl Eppendorf tube and incubated for 5 min on ice. The nuclei were pelleted (1250 g, 4°C, 5 min) and nuclear proteins were extracted in 100 ml extraction buffer (420 mM NaCl, 10 mM HEPES pH 7.9, 0.1 mM EGTA, 0.1 mM F.DTA, 1.5 mM MgC12, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 25% glycerol) on ice for 20 min. Cellular debris was removed by centrifugation (1250 g, 4°C, 5 min) and the supernatant containing nuclear proteins was stored at -70°C.
Eìectrophoretic
mobility shift assay Translocation of HIF-1 into the nucleus of OVCAR-3 cells was detected by incubation of nucleic extracts with labeled oligonocleotide probes representing the HIF-1 consensus binding sequence corresponding to position -1910 and -1942 relative to the human VEGF gene transcription initiation site (VF.GF sense: 5' GACTCCACAGTGCATACGTGGGC-TCCAACAGG 3'; VEGF antisense: CCTGTTG-GAGCCCACGTATGCACTGT-GGAGTC}, and the sequence containing the HIF-1 binding site between nt 3449-3472 within the 3' flanking region of the human EPO gene sequence (EPO sense: 5 -AGCTTGCCC-TACGTGCTGTCTCAG-3'; EPO antisense: CTGA-GACAGCAC-GTAGGGCAAGCT), respectively. A mutated HIF-1 binding site in another EPO enhancer oligonucleotide was used to control specificity of HIF-1 signals (EPOmut sense: 5' GCCCTAATGTCTGC-CTCGCATGGC 3"; F.PO mut antisense: 5' GCCATGC-GAGGCAGACATTAGGGC 3 ). Probes were generated by 3' end labeling of double-strand oligonucleotides (100 ng/μΐ) with digoxigenin-11-ddUTP in TEN buffer (10 in M TRIS-HC1, 1 rriM F.DTA, 0.1 M NaCl, pH 8.00) by 50 U terminal transferase (DIG gel shift kit, Boehringer Mannheim, Germany). Gel shift reactions were performed by mixing 0.5 ng/μΐ probe with nucleic extracts (final concentration of proteins: 5 μg/μl), and 1 μg/μl poly(dl-C') to avoid formation of unspecific protein-DIG-labelcd DNA complexes. Oligonucleotide-protein complexes were separated by electrophoresis on a non-denaturing Polyacrylamide gel for 4 h at 150 V in 0.25 χ TBE buffer (89 mVI TRIS-HCl, 89 mM boric acid. 2 inM FDTA. pi I 8.00). Subsequently, the probes were transferred onto a nylon membrane using a BioRad transblot apparatus (BioRad, München, Germany). Blotting was performed overnight at 1 5 V and at 4°C. Oligonucleotides were fixed onto the dried membranes by UV-crosslinking (0.121 J/cnv for 20 sec). The digoxigenin labeled probes were bound to an AP-conjugated anti-digoxigenin antibody (75 mU/ml). Detection of AP was done by autoradiography of the chemiluminescence produced during enzymatic dephosphorylation of CSPD (100 μg/ml). The chemiluminescent signals were recorded by exposure to an X-ray film for 30 min.
Reagents dNTP-mix, penicillin-streptomycin, primer sets, trypsin-EDTA, M-MLRV superscript reverse transcriptase, Oligo-(dT) 15, and Taq polymerase were purchased from Invitrogen GmbH, Eggenstein, Germany. RPMI was from PA A Laboratories, Coclbc, Germany and fetal calf serum was provided by Riochrom AG, Berlin, Germany. Guanidine isothiocyanate was from Roth, Karlsruhe, Germany. Neopterin was purchased from Schircks Lab., Jona, Switzerland. All other chemicals were from Sigma Chemicals, Deisenhofen, Germany.
Statistics
Results are expressed as mean values ± standard error of the mean (SEM). To test for significance of differences between the mean value of a control vs. the mean value of treated cells, the Student's t-test was used. P-values < 0.05 were considered to be significant.
Results
Effects of neopterin on VEGF and EPO gene expression in ovarian carcinoma
cells Qualitative RT-PCR analyses revealed that both VEGF and EPO gene expression in OVCAR-3 cells were stimulated by neopterin in a time-and dosedependent manner. At least higher concentrations of neopterin (10 and 100 μΜ) exerted a VEGF-and EPOinducing effect in a normoxic environment ( Figures  1A and 2A, respectively ) , although effects of neopterin were most prominent under hypoxic conditions ( Figures IB and 2B . respectively). These observations could be confirmed by the quantitative analyses of VEGF and EPO cDNA as summarized in Table 1 . Application of neopterin resulted in a significant increase of both VEGF and EPO mRNA expression under hypoxic as well as normoxic conditions. It should be noted that the increase (as related to unstimulated controls) in VEGF and EPO cDNA concentrations is more pronounced following neopterin incubations in normoxic medium as compared to the respective treatment in a hypoxic setting.
Activation of the transcription factor HIF-! by neopterin
The effects of neopterin on the translocation of HIF-1 into the nucleus of OVCAR-3 cclls are shown in Figure 3 (normoxic conditions) and Figure 4 (hypoxic conditions). HIF-Î was detectable in normoxic and hypoxic controls. Activation of HIF-1 was further pronounced following tretament of cells with neopterin at increasing amounts as indicated by stronger signals after incubation of nuclear extracts with digoxigenin-11-ddUTP-labeled oligonucleotides corresponding to HIF-1 binding sites in the human VEGF promoter and EPO enhancer respectively. 
Discussion
In the present study we could demonstrate an activating effect of the pteridine compound neopterin on the transcription factor HIF-1 and a subsequent induction of VEGF and EPO gene expression in the human ovarian carcinoma cell line OVCAR-3. Since neopterin is not produced in large amounts by the cancer cells themselves, it is not a classical tumor marker but rather reflects the state of activation of the cellular immune system induccd by the altered surface of the tumor cells. However, apart from being a marker of an activated cellular immune system, neopterin has been shown to exhibit a number of biochemical properties in different cells. It was found to induce tumor necrosis factor-α (TNF-a)-synthesis in human macrophages (20) and rat vascular smooth muscle cells (21 ) . In addition, stimulation of inducible nitric oxide synthase (iNOS) gene expression and nitric oxide (NO)-synthesis in rat vascular smooth muscle cells in response to Pteridines/Vol. 16/No. 4 incubation with neopterin was described (22) . Thus, neopterin seems to represent an endogenous mediator of the cellular immune system that interacts with other agonists and target cells in the course of inflammation.
However, some of these agonists exhibited opposing effects on VFGF as well as EPO synthesis as compared to our own observations. The pro-inflammatory cytokines TNF-a, interleukin-1 β (IL-1 β), and the reactive nitrogen species NO have been shown to decrease VEGF and EPO mRNA levels and to inhibit hypoxiainduced EPO production, respectively (23) (24) (25) . Considering the important role of HIF-1 for VEGF and EPO gene expression, one may speculate an inhibitory effect of these pro-inflammatory substances on HIF-1 availability. Surprisingly, quite the opposite effects of TNF -oc, IL-1 β, and NO have been reported recently. In the human hepatoma cell line HepG2, TNF-a and ILlß strongly increased hypoxia-induced HIF-1 activity as compared to the single effect of hypoxia (26) . Expression of the iNOS gene in proximal tubular cells resulted in HIF-la accumulation suggesting that NO is an activator rather than a suppressor for HIF-1 (27) . Moreover, in both studies, the HIF-1 inducing cffccts of the inflammatory mediators were not restricted to a hypoxic environment. The cytokines as well as NO exerted a HIF-1 stimulatory effect under normoxic conditions, too. Thus, HIF-1 may represent a trans-acting factor in inflammatory processes independent of the cellular p0 2 -This is in congruence with the data found in our study since neopterin proved to be an activator of HIF-1 translocation in normoxic conditions as well. Hellwig-Buergel et al. (26) could not observe an increased synthesis of either VEGF or EPO following TNF-a and IL-1 ß-induced activation of HIF-1. In fact, while VEGF mRNA and protein content were not altered by cytokine treatment in HcpG2 cells. EPO mRNA synthesis and sccrction of EPO protein was even decreased in response to TNF-a and IL-lß, respectively. The authors suggest that other cis-acting elements mediate inhibition of EPO gene expression by cytokines in spite of an increased HIF-1 translocation into the nucleus. Other findings controversial to our data have been reported by Schobersberger and coworkers (18) who could show an inhibitory effect of neopterin on hypoxia-induced EPO synthesis in HepG2 cells. Since they did not observe the state of HIF-1 activity, however, the study does not exclude a promoting effect of the pteridine compound on HIF-1. Intertumorigenic heterogeneities may account for the discrepancies between these observations and our own findings in ovarian carcinomas where activation of HIF-1 was induced by neopterin and led to a subsequent stimulation of VEGF and EPO mRNA expression as well as to an augmented release of both growth factors into the culture supernantants. With respect to VEGF and EPO being two important mediators of vascular angiogenesis (8, 12) , these effects of neopterin may be advantageous to tumor progression and metastasis and consequently detrimental for the tumor-bearing host. Accummulation of neopterin within the tumor microenvironment may thus promote tumor blood flow and an increase in tumor mass. The present data may serve as an explanation for the significant correlation between increased neopterin levels in various body fluids and the unfavorable prognosis in ovarian cancer disease, i.e. patients with elevated neopterin concentrations were charaterized by a shorter survival time (3) (4) (5) 28, 29) .
In summary the present study provides further evidence that neopterin acts as a mediator of angiogenesis within the inflammatory cascade. By stimulating VEGF and EPO synthesis in ovarian carcinoma cells through the activation of the transcription factor HIF-1 in a p0 2 independent fashion, neopterin may contribute to tumor growth.
